ISL
CRL icon

Ingalls & Snyder LLC’s Charles River Laboratories CRL Stock Holding History

Ingalls & Snyder LLC’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-865
Closed -$234K – 441
2024
Q1 		$234K Hold
865
– – 0.01% 389
2023
Q4 		$204K Buy
+865
New +$170K 0.01% 401

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Ingalls & Snyder LLC's CRL Position: Q2 2024 in Review

Ingalls & Snyder LLC sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 865 shares — an estimated $234K sold.

Ingalls & Snyder LLC first reported a position in CRL in Q4 2023 and held it in 2 quarters. The position peaked at $234K in Q1 2024. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Ingalls & Snyder LLC reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 865 Charles River Laboratories shares in Q2 2024, an estimated $234K.
  • Ingalls & Snyder LLC first reported a position in Charles River Laboratories in Q4 2023 and held it in 2 quarters.
  • Ingalls & Snyder LLC's Charles River Laboratories position peaked at $234K in Q1 2024.
  • 665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2024, filed 31 Jul 2024.